BRANFORD, Conn. / Jun 19, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics."
When: June 20, 2025, at 8 a.m. PDT/11 a.m. EDT
This one-hour webinar will explore critical strategies for improving the accessibility, integration, and standardization of data across proteomics platforms. Attendees will learn how to deposit data into public repositories, apply metadata annotation best practices, normalize cross-study datasets, and contribute to global standardization initiatives.
Industry leaders from Quantum-Si, DNAnexus, Olink (a Thermo Fisher Scientific company), and Northwestern University’s Proteomics Center of Excellence will share their perspectives and practical insights through presentations, case studies, and panel discussions.
Key Topics Include:
Featured Speakers:
Hosted by GenomeWeb, this webinar provides a timely forum for researchers, data scientists, and bioinformaticians to align on best practices and influence the future of data standardization in proteomics.
WHERE: Virtual event – registration required.
HOW: To register, please complete the registration form. A confirmation email will be sent upon registration.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$1.10 |
Daily Change: | -0.02 -1.79 |
Daily Volume: | 5,633,880 |
Market Cap: | US$200.820M |
August 05, 2025 June 17, 2025 June 10, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load